Furthermore, the combination of antibodies targeting IL-8 with those targeting EGFR resulted in increased anti-tumor effects, as compared with anti-EGFR alone, in a metastatic human breast carcinoma model in SCID mice [44]. The gene discussed is CXCL8; the disease is breast carcinoma.